Novan Licenses SB204 to Sato for Acne in Japan

Novan Licenses SB204 to Sato for Acne in Japan


Novan, Inc. today announced that the Company has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. , a Japanese company with a prescription pharmaceutical business specializing in dermatology. Upon execution of the agreement, Sato will pay to Novan an initial payment of 1.25 billion JPY for the exclusive rights to develop and commercialize in Japan Novan's topical nitric oxide-releasing product candidate SB204 and related dosage forms for the treatment of acne vulgaris.



from Biotech News